A vial labeled “5 mg semaglutide” may contain as little as 3.8 mg of actual peptide. The difference is the counterion — and almost no one reports it correctly.

1. The Invisible Ingredient

When you buy a peptide, you are almost never buying pure peptide. You are buying a peptide salt — a complex of the peptide molecule with one or more counterions that balance the peptide’s charge and improve stability and solubility.

The most common counterions in the peptide industry are:

• Acetate (CH₃COO⁻): The industry standard for therapeutic peptides
• Trifluoroacetate (TFA, CF₃COO⁻): Common in research-grade peptides from HPLC purification
• Hydrochloride (Cl⁻): Used for some peptide drugs
• Sodium (Na⁺): Used for acidic peptides

These counterions are not impurities — they are an intentional part of the drug substance. But they are also not active pharmaceutical ingredient (API). And their proportion varies widely between manufacturers, batches, and purification methods.

2. The Math That Nobody Does

Consider a semaglutide acetate sample with the following analysis:

• HPLC purity: 99.0%
• Water content: 4.0%
• Acetate content: 10.0%
• Residual TFA: 0.5%

The true peptide content is:

Peptide Content = 99.0% × (1 − 0.04 − 0.10 − 0.005)
                = 99.0% × 0.855
                = 84.6%

A 5 mg vial of this material contains 4.23 mg of semaglutide, not 5 mg. If a compounding pharmacist reconstitutes the vial in 2 mL of bacteriostatic water and draws 0.2 mL for a 0.5 mg dose, the actual delivered dose is 0.423 mg — a 15.4% under-dose.

Now consider the same peptide supplied as TFA salt:

• TFA content can range from 15% to 30% by weight
• TFA is a stronger acid than acetate and binds more tightly to basic residues
• A 5 mg vial of semaglutide TFA with 25% TFA content contains approximately 5 mg of actual peptide

The delivered dose is 30% lower than labeled. This is not a minor variation. It is a clinically significant dosing error.

3. Why Counterion Content Varies So Widely

3.1 Purification Method

Most synthetic peptides are purified by preparative RP-HPLC using TFA in the mobile phase. The peptide elutes as a TFA salt. Converting from TFA to acetate requires:

• Ion exchange chromatography, or
• Multiple lyophilization cycles from acetic acid solution, or
• Precipitation and washing

These conversion steps add cost and time. Many research-grade suppliers skip them, delivering TFA salt directly from HPLC. The TFA content of such material can be 20–35% by weight.

3.2 Lyophilization Conditions

Even for peptides intentionally prepared as acetate salts, the final acetate content depends on:

• The concentration of acetic acid in the final lyophilization buffer
• The number of lyophilization cycles
• The residual moisture content (water can hydrolyze acetate-peptide bonds)
• The peptide’s isoelectric point and number of basic residues

Two manufacturers using the same synthesis and purification can produce material with 8% vs. 15% acetate content, purely due to lyophilization differences.

3.3 The TFA Residue Problem

Even “acetate” peptides often contain residual TFA from HPLC purification. TFA is difficult to remove completely, and residual levels of 0.1–2.0% are common. TFA is more than a counterion — it is also a potential toxicant. The FDA has issued guidance on residual TFA levels in peptide drugs, and high TFA content has been associated with adverse events in injectable peptide products.

4. The Analytical Methods

4.1 Ion Chromatography Best Practices

IC is the gold standard for counterion quantitation. Key method parameters:

• Column: Anion exchange (Dionex IonPac AS11-HC or equivalent)
• Eluent: KOH gradient (1–40 mM)
• Detection: Suppressed conductivity
• Sample preparation: Dissolve 5–10 mg in 10 mL water; inject 25 μL
• Calibration: External standard curve with acetate and TFA standards

4.2 Peptide Content by Amino Acid Analysis

AAA hydrolyzes the peptide into individual amino acids, which are then quantified by HPLC or LC-MS. The total amino acid recovery gives the absolute peptide content. This is the most accurate method for peptide content determination but requires 24-hour hydrolysis and is more expensive than IC.

5. What a Responsible CoA Should Report

A transparent CoA for a peptide product must include:

1. Purity (HPLC area %) — with method details
2. Peptide content (% w/w) — by AAA or qNMR
3. Water content (% w/w) — by Karl Fischer
4. Counterion identity and content (% w/w) — by IC
5. Residual solvents (% w/w) — by headspace GC
6. Assay basis — explicitly stating whether values are on peptide basis or salt basis

Without all six, the CoA is incomplete and the dose is unknown.

6. Conclusion

The counterion trap is the most pervasive dosing error in the peptide industry. It is not fraud — it is a failure of standardization and transparency. Buyers who accept “99% purity” as a dosing metric are systematically under-dosing or, in the case of TFA-heavy material, exposing patients to unnecessary toxicant load. The solution is simple: demand peptide content, not just purity, and verify counterion identity in every batch.